NALLPEN
Pronunciation: naf-SIL-in

What it isPenicillinase-resistant penicillin; methicillin-susceptible staphylococcal infection.
Why this oneIts unusual distinction among antibiotics is enzyme induction strong enough to undermine warfarin.
What limits itPhlebitis and extravasation injury can end IV therapy; renal adjustment is unnecessary.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Staphylococcal / susceptible infection | adult | 500 mg IV q4h; 1 g q4h for severe infection | ||
| Staphylococcal / susceptible infection (IM) | adult | 500 mg IM q4–6h | ||
| Susceptible infection | infants & children <40 kg | 25 mg/kg IM BID | ||
| Susceptible infection | neonates | 10 mg/kg IM BID |
Renal No adjustment needed, including patients on hemodialysis
Hepatic Undefined
Available strengths
Pregnancy Undefined
Lactation Undefined
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 1 g | inj | per unit | not offered | |
| 2 g | inj | per unit | not offered |
Generic entryBy 2023
NO BOXED WARNINGS
Principal riskIt INDUCES CYP3A4, so warfarin fails
Legacy pregnancy categoryB
Defining liabilityAllergy, gastrointestinal effects and agent-specific renal, hepatic, hematologic or interaction risks.